NVO

NOVO NORDISK A S

Healthcare • CIK: 0000353278

Loading...

Market Cap
—
P/E (TTM)
—
Rev Growth (TTM)
—
Net Margin (TTM)
—
FCF Yield (TTM)
—
FCF Margin (TTM)
—

What Changed

View Full Insights
20-F FY 2025 vs 20-F FY 2024
340B Drug Pricing Program Riskhigh (USD 4.2B revenue constrained as provision for...→low (HRSA dismissed ADR petition January 20, 2026; USD...
US GLP-1 and Insulin Net Pricesmedium (US payer rebate pressure increasing in insulin...→medium (average net prices after rebates for full Novo...
GLP-1 Volume Market Sharemedium (competitive pressure emerging in both obesity...→medium (volume market share lost in GLP-1 for both...
Akero Therapeutics Acquisitionno MASH clinical-stage asset in pipeline→acquired Akero Therapeutics at $54 per share (Phase 3...
Illicit GLP-1 Compoundingmedium (GLP-1 drug shortage permitting compounding...→medium (GLP-1 shortage resolved but illicit compounding...

Q1 2026 income statement: verify USD 4.2B 340B revenue recognized (look for...·GLP-1 volume market share in FY 2026 20-F: track whether obesity and diabetes...·US average net price trajectory: monitor rebate percentage trends across...

Filing Intelligence

5.0/10
20-F filed Feb 4, 2026 • FYNone

Executive Summary

Management acknowledges significant pricing pressures and increased rebate demands in the US market, impacting net prices despite underlying demand.. The company is strategically investing in R&D and...

Key Concerns

  • ●Management acknowledges significant pricing pressures and increased rebate demands in the US market, impacting net prices despite...
  • ●Supply chain constraints have improved, but competitive pressures have led to market share loss in the GLP-1 segment.
  • ●The company faces significant risks related to cybersecurity and data breaches, which could lead to substantial financial and reputational...
View Full Quarterly Insights →

LATEST EARNINGS

No earnings in last 90 days

Check back after next 8-K filing

Cash Flow Health

Free Cash Flow0/8 positive
TTM$–
FCF Margin
TTM–
Sector: 0.0%
OCF Margin–
OCF/NI–
CapEx Coverage–
FCF Yield–
FCF Growth (2Y)–
Cash Conversion Cycle
–
View Insights from Latest Filing →View Full Cash Flow Statement →

Capital Allocation & Returns

Total Shareholder Yield
TTM0.0%

Insufficient data

Dividend & Payout Metrics
Dividend Yield (TTM)–
Shows how management rewards shareholders

Operational Efficiency & Returns

Return on Invested CapitalTTM
–
P25MedianP75
(med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
–
Asset Turnover
–
Leverage (1+D/E)
1.00x
D/E: 0.00x
Asset & CapEx Efficiency
Asset-based ROIC formula
Full Analysis

QUARTERLY TRENDS

No data available

Valuation Analysis

Price-to-EarningsTTM
–
Valuation Lenses
Earnings
–
vs – sector
Cash Flow
–
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: –
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap–
EV–
Multi-angle valuation analysis with sector context

Business Quality & Moat

Overall Quality Score
–/100
Unknown

Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)

Returns on Capital

Return on Equity (ROE)
–
8Q:–
Return on Invested Capital (ROIC)
–
8Q:–
vs Sector:-0.0%

Earnings Quality

Cash Conversion

–

OCF / Net Income

FCF Consistency

–

Positive quarters

Competitive Moat Indicators

Pricing Power

Gross Margin–

Capital Efficiency

Invested Capital Turnover–

Working Capital

Cash Conversion Cycle–

Growth Quality & Momentum

Growth Rates

Revenue Growth YoY
N/A
OpInc Growth YoY
N/A
EPS Growth YoY
N/A
FCF 3Y CAGR
N/A

Margin Quality & Sustainability

Moderate
Profitability Cascade
Gross
—
Operating
—
Net
—
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
—
FCF: — | Net: —

Quality = stability + cash conversion + low dilution

Balance Sheet & Solvency

Fortress
Net Debt / EBITDA
Net Cash
(0.0x)Net Cash: $26.46B
Interest Coverage
–
+Net cash position: $26.46B
Balance sheet risk & solvency analysis

Research

All research